title: STRO-1, HOP-26 (CD63), CD49a and SB-10 (CD166) as markers of primitive human marrow stromal cells and their more differentiated progeny: a comparative investigation in vitro.
abstract: There is widespread interest in the use of bone marrow stromal cells (BMSC) for tissue reconstruction and repair and for gene therapy. BMSC represent the differentiated progeny of CFU-F, which however comprise a developmentally heterogeneous population as is reflected in the cellular heterogeneity of the cell populations to which they give rise. We have compared the efficacy of monoclonal antibodies recognising a series of stromal antigens, viz. STRO-1, HOP-26, CD49a and SB-10/CD166, as tools for the enrichment of CFU-F prior to culture and as developmental markers for culture-expanded BMSC. In freshly isolated bone marrow mononuclear cells (BMMNC), the proportion of antigen-positive cells was 27%, 46%, 5% and 19% for STRO-1, HOP-26, CD49a and CD166, respectively. All CD49a(+) cells co-expressed STRO-1. The degree of CFU-F enrichment obtained with anti-CD49a (approximately 18-fold) by a one-pass immunoselection strategy was significantly greater than that of all other antibodies tested. BMSC expressed higher levels of all antigens investigated (except for HOP-26) compared with BMMNC. Expression of STRO-1 and CD49a remained restricted to a subset of BMSC, whereas all BMSC were SB-10/CD166 positive. Treatment with dexamethasone (10 nM), which promotes the differentiation and further maturation of cells of the osteogenic lineage in this cell culture system, increased the expression of CD49a and HOP-26. The CD49a(+) and HOP-26(+) fractions of BMSC were further subdivided by dual-labelling with anti-STRO-1 and B4-78 (an antibody recognising the B/L/K isoform of the enzyme alkaline phosphatase), respectively. By using a variety of criteria, the HOP-26 antigen was identified as CD63, a member of the tetraspanin family of proteins thought to modulate integrin compartmentalisation and signalling.
authors.affiliation: School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK. K.Stewart@bath.ac.uk
authors.forename: Karina
authors.initials: K
authors.lastname: Stewart
authors.forename: Peter
authors.initials: P
authors.lastname: Monk
authors.forename: Susan
authors.initials: S
authors.lastname: Walsh
authors.forename: Carolyn M
authors.initials: CM
authors.lastname: Jefferiss
authors.forename: Julie
authors.initials: J
authors.lastname: Letchford
authors.forename: Jon N
authors.initials: JN
authors.lastname: Beresford
mesh_terms: D020410:Activated-Leukocyte Cell Adhesion Molecule / Q000378:metabolism*; D000911:Antibodies, Monoclonal / Q000378:metabolism; D000954:Antigens, Surface / Q000378:metabolism*; D015415:Biomarkers; D001854:Bone Marrow Cells / Q000276:immunology*; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D006801:Humans; D039423:Integrin alpha1 / Q000378:metabolism*; D017154:Stromal Cells / Q000276:immunology*
chemical_list: D020410:Activated-Leukocyte Cell Adhesion Molecule; D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D015415:Biomarkers; D039423:Integrin alpha1